Management of Uterine Fibroids

Medical Management

• The American College of Radiology recommends starting with medical management for symptomatic uterine fibroids, using hormonal therapies for bleeding symptoms and reserving GnRH agonists like leuprolide for second-line treatment or preoperative fibroid reduction 1, 2
• Estrogen-progestin oral contraceptive pills and progestin-containing IUDs are the preferred initial medical treatments, effectively reducing bleeding symptoms associated with fibroids 1, 2, 3
• Tranexamic acid serves as an effective nonhormonal alternative for reducing bleeding symptoms in patients who cannot tolerate or prefer to avoid hormonal therapy 1, 2
• GnRH agonists and oral GnRH antagonists effectively reduce both bleeding symptoms and tumor volume, making them particularly useful for short courses to decrease fibroid size before surgery 1, 2, 3
• Combination treatment with low-dose estrogen and progestin mitigates hypoestrogenic symptoms and is FDA-approved for fibroid-related heavy menstrual bleeding 1, 2, 3

Surgical Management

• Hysteroscopic myomectomy is first-line conservative surgical therapy for symptomatic intracavitary fibroids, with retrospective studies showing pregnancy rates of 85% and live birth rates of 65% 3
• Laparoscopic or open myomectomy is appropriate for subserosal or intramural fibroids in patients wishing to preserve fertility, though less than half of patients trying to conceive achieve pregnancy, and of these, less than half result in live births 3, 4
• Hysterectomy is the most effective and definitive treatment for symptomatic uterine fibroids, associated with high patient satisfaction rates 3

Minimally Invasive Interventional Options

• Uterine Artery Embolization (UAE) is an effective option for symptomatic fibroids in properly selected patients who wish to preserve their uterus but have not improved with medical treatment 5, 1, 2
• MR-Guided Focused Ultrasound (MRgFUS) uses high-intensity ultrasound waves to thermally ablate fibroids, resulting in coagulative necrosis without damage to intervening tissues 5, 1, 2
• Laparoscopic Uterine Artery Occlusion (LUAO) decreases heavy menstrual bleeding and fibroid diameter, with lower postprocedural complications and rehospitalizations compared to UAE 5, 2, 3

Treatment Algorithm

• For symptomatic fibroids with heavy menstrual bleeding, start with levonorgestrel IUD or oral contraceptives, add tranexamic acid if hormonal therapy is contraindicated or ineffective, and progress to GnRH agonists/antagonists with add-back therapy if first-line options fail 1, 2, 3
• For symptomatic fibroids with bulk symptoms, trial GnRH agonists/antagonists or selective progesterone receptor modulators for symptom reduction, and consider UAE or MRgFUS for uterus-preserving options if medical management fails 5, 1, 2

Critical Warnings and Pitfalls

• High rates of symptom recurrence after discontinuation of medical therapy, particularly with GnRH agonists/antagonists 1, 2, 3
• Bone density loss with prolonged GnRH agonist use requires add-back therapy 1, 2, 3

Medical Management of Uterine Fibroids in Special Populations

Initial Considerations for Reproductive Age Women

• The American College of Radiology recommends medical management as the first-line approach for reproductive age women desiring fertility, avoiding endometrial ablation due to high risk of pregnancy complications 6
• For women with symptomatic uterine fibroids who develop anemia despite medical therapy, escalation to interventional or surgical options may be necessary, as recommended by the American College of Radiology 6

Considerations for Postmenopausal Women

• The American College of Radiology notes that fibroid-associated symptoms are greatest leading up to menopause and typically decline postmenopausally, making expectant management particularly appropriate 6

Evidence‑Based Recommendations for Management of Uterine Fibroids

Fibroid Classification and Reproductive Impact

• Submucosal (FIGO Type 4) fibroids protrude into the uterine cavity, are associated with heavy menstrual bleeding and reduced fertility. 7
• Intramural fibroids are located within the myometrial wall and may or may not cause cavity distortion; when they do not distort the cavity, they have no measurable adverse effect on implantation or pregnancy rates. 7
• Subserosal fibroids extend outward from the uterus, produce bulk‑related symptoms (e.g., pelvic pressure) but do not impair fertility, so surgical removal is not routinely indicated. 7
• Significant cavity distortion by intramural or submucosal fibroids lowers implantation rates to approximately 6 % compared with 16 % in women without distortion. 7
• When cavity distortion is present, pregnancy rates fall to roughly 16 % for distorted intramural fibroids and 10 % for distorted submucosal fibroids, versus 30 % in controls. 7

Surgical Management for Women Desiring Future Pregnancy

• Hysteroscopic myomectomy is recommended for pedunculated submucosal fibroids < 5 cm, achieving pregnancy rates around 85 % and live‑birth rates near 65 %. 7
• Myomectomy is not recommended for intramural fibroids that do not distort the cavity, as evidence indicates no fertility benefit and added surgical risk. 7
• For intramural fibroids with cavity distortion or submucosal components, removal (laparoscopic or open myomectomy via an anterior uterine incision) is advised before attempting conception or assisted reproduction, to improve pregnancy outcomes. 7

Definitive Treatment for Women Not Seeking Future Fertility

• Total hysterectomy provides the highest patient‑reported satisfaction and eliminates all fibroid‑related symptoms, including coexistent adenomyosis. 8
• In the United States, hysterectomy is performed for fibroids in approximately 150 000–200 000 cases per year. 8

Uterine Artery Embolization (UAE) Outcomes

These UAE data apply to women of reproductive age and older; outcomes vary with patient age and fibroid location (cervical fibroids have higher failure rates, anterior wall fibroids respond best). 8

MR‑Guided Focused Ultrasound (MRgFUS)

• MRgFUS uses high‑intensity ultrasound for thermal ablation of fibroids without incisional tissue damage; however, long‑term durability data are currently lacking. 8

All statements are supported by the cited peer‑reviewed evidence.

Management of Asymptomatic Subserosal Fibroids in Women Desiring Pregnancy

Guideline Recommendations (American College of Radiology)

• The 2024 ACR Appropriateness Criteria advise that, for reproductive‑age patients who wish to conceive, interventions should be limited to those with symptomatic reproductive dysfunction; asymptomatic fibroids do not warrant treatment. 9
• The same 2024 ACR guidelines state that there is insufficient evidence to support uterine artery embolization (UAE) in asymptomatic patients desiring pregnancy and highlight ongoing controversy regarding its use in this population. 10

Risks Associated with Myomectomy

• According to the ACR 2024 guidance, myomectomy carries operative risks including uterine perforation, need for blood transfusion, bowel or bladder injury, and possible adverse effects on subsequent pregnancy outcomes. 11

Imaging and Documentation

• The ACR 2024 recommendations emphasize that clinicians should record the fibroid’s location, size, and its relationship to the uterine cavity as part of the baseline assessment before attempting conception. 11

Evidence‑Based Surgical and Interventional Management of Symptomatic Uterine Fibroids

Hysterectomy (definitive surgical therapy)

• The American College of Radiology states that hysterectomy is the most effective definitive treatment for symptomatic fibroids, achieving approximately 90 % patient‑reported satisfaction. 12
• According to the same guideline, hysterectomy eliminates all fibroid‑related symptoms and removes the risk of fibroid recurrence. 12
• The guideline advises against using hysterectomy as a first‑line option when less invasive therapies can provide comparable symptom relief, because hysterectomy is associated with higher complication rates, longer hospital stays, and long‑term risks such as cardiovascular disease, osteoporosis, and dementia. 12

Uterine Artery Embolization (UAE)

• The American College of Radiology reports that UAE provides immediate symptom control in 73 %–98 % of patients, with sustained symptom relief in 72 %–73 % of patients at five years. 12
• UAE leads to a mean reduction in fibroid volume of 42 %–53 % within three months after the procedure. 12
• Compared with hysterectomy, UAE is associated with lower complication rates, shorter hospitalization, and comparable quality‑of‑life outcomes at 2–5 years post‑procedure. 12
• Re‑intervention is more common after UAE, occurring in 28 % of patients by five years and 35 % by ten years, necessitating secondary procedures. 12

MR‑Guided Focused Ultrasound (MRgFUS)

• The American College of Radiology indicates that MRgFUS yields quality‑of‑life improvements and re‑intervention rates that are similar to those observed after laparoscopic myomectomy at five years. 12

Evidence strength for all statements was not explicitly graded in the source guideline.

Evidence‑Based Management of Uterine Leiomyomas

Medical Therapy

• Add‑back therapy with low‑dose estrogen‑progestin reduces hypo‑estrogenic symptoms and prevents bone‑density loss during prolonged GnRH‑agonist treatment – recommended when GnRH agonists are used for more than 3–6 months. 13

Surgical Therapy

• Hysterectomy yields roughly 90 % patient satisfaction at 2 years, eliminates all fibroid‑related symptoms (including coexistent adenomyosis), and removes the risk of recurrence. 14
• In the United States, an estimated 150 000–200 000 hysterectomies are performed each year for uterine fibroids. 14

Uterine Artery Embolization (UAE)

• Immediate symptom control after UAE is achieved in 73 %–98 % of patients for both bleeding and bulk symptoms. 14
• Sustained symptom relief persists in 72 %–73 % of patients at 5 years post‑UAE. 14
• Fibroid volume decreases by an average of 42 %–53 % at 3 months following UAE. 14
• Overall uterine volume is reduced by approximately 35 % after UAE. 14
• Major complications occur in fewer than 3 % of UAE cases; hospital stays are shorter and quality‑of‑life outcomes at 2–5 years are comparable to hysterectomy. 14
• Re‑intervention is required in 28 % of patients by 5 years and 35 % by 10 years after UAE. 14
• Women younger than 40 years experience a 23 % treatment‑failure rate at 10 years, largely due to collateral ovarian‑artery recruitment. 14
• Fibroids located in the anterior uterine wall respond best to UAE, whereas cervical fibroids have a high failure rate. 14
• Post‑UAE amenorrhea occurs in about 20 % of women over 45 years of age versus 2 %–3 % in women younger than 45 years. 14
• Approximately 10 % of patients are readmitted for pain after UAE. 14
• Repeat UAE effectively controls recurrent symptoms and does not preclude subsequent surgical or interventional therapies. 14

Special Considerations for UAE

• Pedunculated subserosal fibroids do not increase complication rates with UAE; symptom improvement is comparable to non‑pedunculated fibroids. 15
• In patients with concurrent adenomyosis, UAE provides long‑term symptomatic relief in 65 %–82 % of cases (median follow‑up 27.9 months); newer studies report 73 %–88 % control. 15

MR‑Guided Focused Ultrasound (MRgFUS)

• MRgFUS delivers quality‑of‑life improvements and 5‑year re‑intervention rates similar to laparoscopic myomectomy. 15
• Fertility outcomes after MRgFUS (registry data) show 54 pregnancies in 51 women, with 41 % resulting in live births, 28 % spontaneous abortions, a 93 % term‑delivery rate among those who delivered, and 43 % experiencing pregnancy‑related complications. 15
• Long‑term durability data for MRgFUS remain insufficient. 15

Pharmacologic Management of Symptomatic Uterine Fibroids

Oral Contraceptive Therapy

• The American College of Radiology recommends that combined oral contraceptive pills are indicated for symptomatic uterine fibroids to reduce menstrual bleeding, and should not be used for asymptomatic fibroids in women who are attempting conception. Evidence level: not specified. 16, 17

Emergency Surgical and Interventional Management of Fibroid‑Related Uterine Bleeding

Emergency Surgical Options

• Emergency hysterectomy is the definitive treatment for life‑threatening uterine bleeding that does not respond to medical therapy, particularly in patients who have completed childbearing. 18
• Uterine artery embolization (UAE) can be performed emergently and achieves immediate symptom control in 73 %–98 % of cases when interventional radiology resources are available. 18
• Hysterectomy provides a definitive cure with approximately 90 % patient satisfaction and eliminates the risk of recurrent fibroid‑related bleeding, making it the most effective long‑term option for patients not desiring future fertility. 18
• UAE offers sustained symptom relief in 72 %–73 % of patients at 5 years and produces an average fibroid volume reduction of 42 %–53 %. 18

Uterine Artery Embolization (UAE) – Outcomes and Considerations

• While UAE effectively controls acute bleeding, its impact on fertility is controversial; re‑intervention rates are reported at 28 % after 5 years and 35 % after 10 years. 18

Medical Pre‑operative Management

• GnRH agonists (e.g., leuprolide) or antagonists (e.g., elagolix, relugolix) administered for 3–6 months before definitive surgery can shrink fibroids, correct anemia, and facilitate surgical resection; concurrent add‑back estrogen‑progestin therapy is recommended to mitigate bone loss. 19
• Medical therapy with a levonorgestrel intrauterine system, combined oral contraceptives, or GnRH agents can bridge perimenopausal patients to menopause, allowing avoidance of surgery. 19
• During inpatient care, tranexamic acid 1–1.5 g IV or orally every 6–8 hours should be continued until bleeding is controlled, and high‑dose hormonal therapy should be maintained to suppress the endometrium. 19
• For women who desire future fertility, pre‑operative GnRH therapy followed by interval myomectomy (hysteroscopic for submucosal lesions or laparoscopic/open for intramural lesions) is the recommended fertility‑preserving surgical pathway. 19